Abstract
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Current Pharmaceutical Biotechnology
Title:Brain Drug Delivery Systems for Neurodegenerative Disorders
Volume: 13 Issue: 12
Author(s): E. Garbayo, E. Ansorena and M.J. Blanco-Prieto
Affiliation:
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Abstract: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Export Options
About this article
Cite this article as:
Garbayo E., Ansorena E. and Blanco-Prieto M.J., Brain Drug Delivery Systems for Neurodegenerative Disorders, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341761
DOI https://dx.doi.org/10.2174/138920112803341761 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder
Current Alzheimer Research Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Editorial: New Avenues and Therapeutic Strategies for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Preface [Hot topic: Protein Misfolding in the Amyloidoses and other Disorders (Guest Editor: David R. Howlett)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Retinal Degenerations: From Cell Signaling to Cell Therapy; Pre-Clinical and Clinical Issues
Current Gene Therapy Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson’s Disease
Current Neuropharmacology IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Current Alzheimer Research